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Background 
As approximately 80% of patients with acute myeloid leukaemia (AML) have high activity of Bruton’s Tyrosine 
Kinase (BTK) in their blasts, which renders them sensitive to the oral BTK inhibitor ibrutinib in-vitro, we 
sought to develop the biologic understanding of the BTK pathway in AML to identify clinically relevant 
diagnostic information that may define a subset of patients that should respond to ibrutinib treatment. 
  
Methods 
We determined the activity of BTK in response CD117 activation in primary AML blasts. Furthermore we 
investigated the effects of ibrutinib on CD117 induced BTK activation, downstream signalling, adhesion to 
primary bone marrow mesenchymal stromal cells and  proliferation of AML. 
  
Findings 
Ibrutinib inhibits CD117 driven proliferation of primary AML blasts. CD117 activation increases BTK activity 
in human AML. Furthermore ibrutinib inhibits CD117 induced activity of BTK and downstream kinases. 
Functionally we report that in-vitro activation of CD117 in CD117 expressing AML blasts which leads to 
adherence of the blasts to the cytoprotective bone marrow microenvironment stromal cells is inhibited by 
ibrutinib.  
  
Interpretation 
As we begin first in man clinical trials of ibrutinib in AML the pre-clinical data suggest not all patients will 
respond. Here we provide evidence that in AML, BTK has specific pro-tumoral biologic actions downstream of 
surface CD117 activation which are inhibited by ibrutinib. Accordingly we propose that patients with AML 
whose blasts express CD117 should be considered for forthcoming clinical trials of ibrutinib. 
 
 
Funding 
The authors thank the Worldwide Cancer Research, The Big C, the National Institutes for Health Research 
(UK), the Humane Research Trust and the Department of Higher Education and Research of the Libyan 
Government for funding 
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Introduction 
Acute myeloid leukemia (AML) comprises a morphologically and biologically heterogeneous group of tumours. 
However despite this apparent diversity comprehensive analysis of AML genomes has suggested that AML is 
not a disease caused by hundreds of mutations, but in fact only a few (1).  Furthermore AML appears to rely on 
common programs of self-renewal downstream of the driver oncogene (2). Taken together these observations 
would suggest that mechanistically common therapeutic approaches are likely to be applicable to broad 
populations of patients with AML, regardless of the identity of the driver oncogene/s involved.  
 
Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase that belongs to the Tec family and has an 
important function in a number of benign and malignant cells of the haematopoietic system (3-5).  Moreover, 
recent phase 1 and 2 studies of the irreversible oral BTK inhibitor, ibrutinib have demonstrated promising 
clinical activity and tolerability against a variety of B-cell malignancies including, chronic lymphocytic 
leukemia (CLL), mantle cell lymphoma, hairy cell leukaemia, multiple myeloma and diffuse large B-cell 
lymphoma in younger and older patients alike (6-14).  Furthermore, it is now clear that the mechanism of action 
[MOA] of ibrutinib is multifactorial in nature with a significant component of its function in lymphoid 
malignancy involving disruption of the interaction between the tumour cell and the microenvironment that 
protects it. Recently our group and others have shown that there is high BTK phosphorylation and RNA 
expression in AML (15-17). Moreover, our recent study described for the first time that ibrutinib and BTK-
targeted RNA interference functionally reduced factor-induced proliferation of both AML cell lines and primary 
AML blasts, as well as reducing AML blast adhesion to BMSC (17). First in man studies of ibrutinib treatment 
in AML are due to begin in the near future. 
 
CD117 is a precursor stage marker expressed on circa 80% of all AML blasts (18, 19) and in routine clinical 
practice commonly forms part of the immunophenotyping panel for AML diagnosis (20). CD117 functions to 
enhance the adhesion of AML blasts to fibronectin and augments fibronectin-mediated anti-apoptotic and 
proliferative signals (21, 22).  In non-malignant myeloid cells CD117 coordinates mast cell activation (23) and 
stimulates the chemotaxis, integrin up-regulation, and survival of basophils (24). Moreover, CD117 mediates 
BTK phosphorylation and downstream survival signals in erythroid progenitors which protects against apoptosis 
signals (25).   
 
In this study we dissect the intracellular signalling cascade downstream of CD117 activation, specifically the 
effects on fibronectin (FN)-mediated AML blast proliferation and adhesion. Furthermore in light of upcoming 
studies of ibrutinib in AML and the ready availability to the physician on the day of diagnosis of the presence or 
absence of CD117 expression on the AML blast surface we investigate the function of CD117 activation on 
AML survival in response to BTK inhibition. 
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Methods 
 
Primary human AML 
AML blasts were obtained from 29 unselected patients attending our hospital (between January 2010 and 
February 2014) who consented to give bone marrow or blood for research following informed consent and 
under approval from the UK National Research Ethics Service (LRECref07/H0310/146).  Patients 
characteristics including WHO diagnosis, previous treatment (or not) and age were collected (Table1).  For 
primary cell isolation, heparinized blood was collected from patients and human peripheral blood mononuclear 
cells (PBMCs) isolated by Histopaque (Sigma-Aldrich, Gillingham, UK) density gradient centrifugation. AML 
samples that were less than 80% blasts were purified using the CD34 positive selection kit (denoted by * in 
Table 1).   Cell type was confirmed by microscopy and flow cytometry. We obtained hematopoietic CD34+ 
cells from two sources, Stem Cell Technologies (Cambridge, UK) and patients.  Positive selection of CD34+ 
cells was isolated from PBMCs using a CD34 positive selection kit (Miltenyi Biotec, Bisley, UK) as previously 
described (26).  Cell type was confirmed by microscopy and flow cytometry.   
  
Human bone marrow stromal cells (BMSC) were isolated by bone marrow aspirates from AML patients.  
Mononuclear cells were collected by gradient centrifugation and plated in growth medium containing RPMI and 
20% FBS and 1% l-glut (Life Technologies, Paisley, UK) . The non-adherent cells were removed after 2 days. 
When 60%-80% confluent, adherent cells were trypsinised and expanded for 3-5 weeks. BMSCs were checked 
for positive expression of CD105, CD73, and CD90 and the lack of expression of CD45 and CD34 by flow 
cytometry as previously described (17).  
 
Materials 
Anti-phosphorylated and pan CD117, AKT, BTK and MAPK antibodies were purchased from Cell Signaling 
Technology (Cambridge, USA). We also purchased anti-BTK (phospho Y223) antibody from R&D Systems 
(Abingdon, UK). Anti-CD34-PE, anti-CD90-FITC, anti-CD73-PE, anti-CD105-APC antibodies were purchased 
from Miltenyi Biotec . All other antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, USA).  
Ibrutinib was obtained from Selleck Chemicals. Stem cell factor (SCF) and fibronectin were purchased from 
Life Technologies. All other reagents were obtained from Sigma-Aldrich , unless indicated. 
 
Western immunoblotting. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analyses were performed as 
described previously. Briefly, whole cell lysates as well as nuclear and cytosolic were extracted and sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis separation performed (27). Protein was transferred to 
nitrocellulose and Western blot analysis performed with the indicated antisera according to their manufacturer’s 
guidelines 
 
Proliferation/death assays  
Cells were treated with different doses of ibrutinib then viable numbers measured with Cell TiterGlo (Promega, 
Southampton, UK).  BrdU Cell Proliferation Assay Kit was purchased from Cell Signaling Technology.  Flow 
cytometry for measuring apoptosis was performed on the Accuri C6 flow cytometer (BD Biosciences, Oxford, 
UK). Samples were collected and stained with annexin- V and propidium Iodide (PI) (Abcam, Cambridge, UK), 
followed by detection. For the AML-BMSC co-cultures AML cell viability was measured using flow cytometry.  
After exclusion of BMSC by electronic gating using forward scatter the extent of AML cells apoptosis was 
measured using annexin-V.  
 
BMSC/fibronectin-AML cell adhesion assay 
BMSCs were grown in 96-well plates. Primary AML cells were incubated with 2.5 µM calcein-AM for 1 h at 
37°C and 5% CO2. The fluorescence-labeled AML cells were added into stromal cell coated 96-well plates and 
incubated for the indicated time points. Non-adherent calcein-labeled cells were removed by gently washing and 
adherent cells were quantitated in a fluorescence multi-well plate reader. For AML blast adhesion onto 
fibronectin (FN), 96 well plates were coated with 10 mg/ml FN for 1 h before the fluorescence-labeled AML 
cells were added. Again non-adherent calcein-labeled cells were removed by gently washing and adherent cells 
were quantitated in a fluorescence multi-well plate reader. 
 
Quantification of BTK activity by immunocytochemistry 
Relative activity of phosphorylated versus total BTK, was measured by immunocytochemistry as previously 
described (20). Briefly, 2 x 104 AML cells were fixed onto microscope slides using 4% (w/v) paraformaldehyde. 
Fixed cells were incubated with rabbit anti-human primary monoclonal antibodies (mAbs) against pBTK 
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(Tyr223) and goat anti-human primary mAbs against total BTK, or goat anti-human primary followed by 
incubation with Alexa Fluor goat anti-rabbit and rabbit anti-goat IgG secondary antibodies (Molecular Probes, 
Life Technologies). Image analyses and quantification of pBTK and BTK staining intensity was performed 
using Image J 1.46 software (National Institute of Health, Bethesda, USA). 
 
Statistical analyses 
The Mann-Whitney test was used to compare test groups where stated.  Results where P < 0.05 were considered 
statistically significant. Pearson’s correlation analysis was used to investigate the relationship between 
phosphorylated BTK and % CD117 expression. For Western blotting the data are representative images of 3 
independent experiments. 
 
Role of the funding source 
The funding sources for this study had no involvement in study design or in the collection, analysis, and 
interpretation of the data or in the writing of the report or in the decision to submit the paper for publication. 
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Results 
Ibrutinib inhibits CD117 driven proliferation of primary AML blasts 
We recently reported that nanomolar concentrations of ibrutinib inhibit primary human AML proliferation and 
adhesion in-vitro in approximately 80% of non-selected primary AML patient samples tested (17). Here we first 
examined the role of ibrutinib in regulating CD117 induced proliferation. CD117 mediated proliferation (as 
measured by BrdU incorporation) in primary CD117 expressing AML blasts is inhibited by ibrutinib (Figure 
1A). Conversely CD117 negative AML blasts did not proliferate in response to CD117 activation and ibrutinib 
had no significant effect on the proliferation of these AML cells (Figure 1B).  In addition, CD117 activation 
increased normal CD34+ haematopoietic progenitor cell (HPC) proliferation, which was also significantly 
inhibited by ibrutinib (Figure 1C). Data were normalised to DMSO treated cells (The line through the data 
indicates the median and the Mann Whitney test was used to determine statistical significance between SCF and 
ibrutinib+SCF treatment groups). We next showed that as little as 100nM of ibrutinib inhibits CD117 induced 
proliferation in CD117 positive AML. An anti-proliferative effect was only seen in CD117 negative AML at a 
concentration of 5000nM and is likely non-specific (Figure 1D and 1E). Data were normalised to DMSO treated 
cells. The line through the data indicates the median. Proliferation at varying concentrations of ibrutinib were 
compared with DMSO treated control by Mann Whitney test (* = P<0.05).  A scatterplot (Figure 1F) shows the 
relationship between pBTK and percentage CD117 (%CD117) expression in human AML blasts (patients n=24; 
correlation coefficient r=0.63). Table 1 shows the half maximal inhibitory concentration (IC50) of ibrutinib 
induced AML cell death (measured by by CellTitre-GLo as described in our previous manuscript (17)). For 
concentrations of ibrutinib <10μM %CD117 expression is variable (range 18 to 92), whereas for concentrations 
of ibrutinib >10μM  %CD117 expression was zero (Figure 1G).  Taken together these results show that ibrutinib 
inhibits CD117 mediated AML proliferation. (8, 14) 
 
CD117 activation increases BTK activity in human AML  
As CD117 activation has been shown to regulate BTK activity in haematopoietic progenitor cells (HPC) we 
investigated BTK activation in AML and downstream pro-survival and proliferation signalling. CD117 is 
expressed in circa 80% of our AML patient samples in keeping with previously published observations (18), 
where CD117 positivity is defined as > 10% (table 1) (28). Recently we reported that approximately 80% of 
AML have constitutive BTK activity as measured by levels of phosphorylated BTK (pBTK) expression in 
primary samples (17). Next to determine whether CD117 activation increases activity of BTK in AML we 
serum starved CD117 positive AML blasts for 4 hours before treatment with stem cell factor (CD117 ligand or 
SCF) for various times up to 30 minutes. Western blot analysis demonstrates that CD117 activation induces 
pBTK from 5-30 minutes above control untreated cells in CD117 positive AML but not in CD117 negative 
AML (Figure 2A and 2B).  
 
Ibrutinib inhibits CD117 induced activation of BTK and downstream kinases. 
Next we asked whether ibrutinib can inhibit CD117 mediated proliferation signals. To do this we examined the 
effect of increasing doses of ibrutinib on CD117 activated AML and analysed phosphorylation of CD117, BTK, 
AKT and MAPK in CD117 positive AML and CD117 negative AML samples. The results show that CD117 
activation induced phosphorylation of CD117 which was not inhibited by ibrutinib however downstream pBTK, 
pAKT and pMAPK were all inhibited at 100 nM or above of ibrutinib in CD117 positive blasts (Figure 3). In 
contrast in the CD117 negative AML we found that pBTK and CD117 levels were undetectable and that the 
levels of pAKT and pMAPK were not affected by any dose of ibrutinib up to 1000 nM (Figure 3). Taken 
together these observations confirm that in CD117 positive AML CD117 mediated activation of pBTK, pAKT 
and pMAPK is inhibited by treatment with ibrutinib. 
 
Ibrutinib blocks adhesion of AML blasts to cytoprotective bone marrow stromal cells (BMSC) 
CD117 activation functions in part by supporting AML adhesion to BMSC (21). Furthermore BMSC provide 
protection from standard cytotoxic chemotherapy (17, 22). Therefore we examined the role of ibrutinib in 
regulating CD117 mediated adhesion to cytoprotective BMSC. AML/BMSC interaction was assessed by calcein 
AM cell adhesion assay. As previously reported, in our primary samples CD117 activation increases adhesion of 
CD117 expressing AML blasts to BMSC (Figure 4A). Next we examined the effect of ibrutinib on CD117 
mediated AML adhesion to BMSC. CD117 positive and CD117 negative AML blasts were pre-treated with 
ibrutinib (500 nM) and then co-cultured with BMSC in the presence of or absence of CD117 activation. CD117 
mediated AML blast adhesion is significantly inhibited by ibrutinib at 500 nM (Figure 4B). Ibrutinib also 
inhibited CD117 mediated adhesion of non-malignant CD34+ HPC to BMSC (Figure 4C). Next we examined 
the apoptotic response of CD117 expressing AML blasts co-cultured with BMSC in the presence of CD117 
activation and ibrutinib for 72 hours. The co-culture was removed from the 12 well plate and antibody to CD34 
was used to distinguish the AML blasts from the BMSC and annexin V was used to examine apoptosis. Figure 
4D shows that ibrutinib alone increased AML blast apoptosis over control untreated co-cultures. Taken together 
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we find that ibrutinib inhibits AML blast adhesion to the underlying cytoprotective BMSC through its action on 
CD117 mediated signalling. 
 
The interaction between AML blasts and the bone marrow microenvironment is critical in regulating tumour 
survival and chemotherapy resistance. Inhibiting AML blast adhesion to BMSC via the VLA4-
VCAM/fibronectin interactions is associated with improvements in tumour cytotoxicity and increasing 
sensitivity to chemotherapy (22). To determine if ibrutinib functions to inhibit VLA4-VCAM/fibronectin 
interactions downstream of CD117 activation in AML we examined primary AML adhesion to fibronectin (FN) 
coated plates. Figure 4E shows that CD117 positive AML blasts (but not primary non-malignant CD34+ HPC or 
CD117 negative AML; supplementary Figure 1 A and C) increase adhesion to FN in the presence of CD117 
activation. When we repeated these experiments in the presence of ibrutinib, CD117 mediated FN adhesion was 
inhibited in CD117 expressing AML (Figure 4F) (but not in primary CD34+HPC or CD117 negative AML; 
supplementary Figure 1 B and D). To demonstrate the specificity of the observed ibrutinib effect, ibrutinib-
treated cells were then treated with PMA (which results in adhesion via protein kinase C-activated integrin 
activation). Figure 4G shows that ibrutinib cannot inhibit PMA induced AML adhesion to FN. Finally others 
have reported that CD117 activation in combination with culture on FN-coated plates increases AML 
proliferation (21). Therefore we examined the effects of ibrutinib on CD117 mediated and FN-mediated 
proliferation. AML proliferation in response to CD117 activation in combination with FN was inhibited by 
ibrutinib (supplementary Figure 2).  
 
Discussion 
 
Here we report that in human AML ibrutinib inhibits the CD117 activation pathway and functions to disrupt 
pro-survival signals from the microenvironment to promote de-adhesion of malignant cells from the BMSC and 
subsequent cell death. 
 
Currently available curative therapeutic strategies for AML are intensive and toxic and generally only widely 
applicable to younger fitter patients. However AML is primarily a disease of the elderly with a median age at 
diagnosis in the Swedish Acute Leukaemia Registry of 72 years (quartile values, 60-79 years; range, 16-97 
years) (29).  Intensive chemotherapy given with curative intent is not easily deliverable to older patients and as 
such outcomes presently remain dismal for the majority group of older patients with the disease (30). 
Accordingly to improve the prognosis for all patients, (including older patients with AML), there is a 
requirement for tumour targeted treatments with improved efficacy and reduced toxicity. Such therapies will 
result from a better understanding of the biology of AML.  
 
BTK is a cytoplasmic tyrosine kinase widely expressed in hematopoietic cells and long known to be critical in B 
cell differentiation and survival pathways. BTK is a member of the BTK/Tec family of tyrosine kinases (31). 
BTK activation has been implicated in a variety of haematopoietic cellular responses and there is a growing 
literature defining the role of BTK in HPC and cells of the myeloid compartment (25, 32, 33). In our previous 
work we showed that ibrutinib could inhibit AML colony formation and survival (17). In this study we develop 
on these findings to investigate upstream mediators (including cell surface receptors) and downstream 
consequences of BTK activation and inhibition. 
 
CD117 is a type III receptor tyrosine kinase operating in cell signal transduction in several cell types(23, 34, 
35). Upon activation (phosphorylation) CD117 initiates a downstream phosphorylation cascade ultimately 
activating various transcription factors depending on the different cell type. In a number of cell types 
phosphorylated CD117 has been shown to use multiple non-receptor tyrosine kinases including BTK, SHIP1/2, 
PLCY2, PI3K, SYK and SRC kinases (25, 36, 37), to regulate apoptosis, cell differentiation, proliferation, 
chemotaxis, and cell adhesion (38). On activation BTK auto-phosphorylates at tyrosine Y223. We were able to 
detect phosphorylation at BTK Y223 in response to activation of CD117 and furthermore this was inhibited by 
ibrutinib. The BTK tyrosine Y551 residue is phosphorylated directly by upstream tyrosine kinases and 
phosphorylation at Y551 should not be affected by ibrutinib, however, immunoblots for BTK Y551 
phosphorylation were not informative.  CD117 is expressed on the cell surface of approximately 80% of cases 
of AML (18), and here we report that CD117 activation in AML links via BTK to downstream pro-tumoral 
signals.  
 
The oral BTK inhibitor ibrutinib appears active and well tolerated in patients with chronic lymphocytic 
leukemia (CLL) and mantle cell lymphoma with limited grade 3 and 4 toxicity (13, 14). Ibrutinib functions 
primarily in these B cell malignancies by perturbing the interactions between the tumour and its 
microenvironment (39). Here we found that ibrutinib was able to inhibit CD117 mediated BMSC adhesion to 
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AML cells at concentrations similar to those that have been reported to inhibit adhesion of CLL cells to BMSC 
(8). Others have also shown that CD117 activation can increase AML adhesion to fibronectin (21), and we have 
previously shown that inhibition of AML/BMSC interactions using ibrutinib can increase AML susceptibility to 
daunorubicin and cytosine arabinoside (17). Taken together this argues that ibrutinib may show clinical efficacy 
in patients at least in part by disrupting the CD117 mediated AML/BMSC interaction.  
 
In patients with CLL receiving ibrutinib the disruption of tumour/BMSC interaction is associated with a 
(usually) transient rise in the circulating leukaemia cell count in the peripheral blood (14). Given the relatively 
small size of CLL cells this is unlikely to have a negative clinical consequence. AML blasts are however larger 
and a high circulating white count in AML can be associated with leucostasis and consequent risk of micro-
infarction, local hypoxemia, bleeding and death. Therefore because of these in-vitro observations regarding 
AML and the BMSC it seems likely that if ibrutinib is effective in AML patients we will observe a rising blast 
count in the peripheral blood in some patients and care should be taken at least initially to monitor for and 
prevent/treat drug-induced hyperleucostasis.  Ultimately though, release of AML leukemic cells from their bone 
marrow microenvironment niche should destabilise their survival mechanisms and render them more sensitive to 
chemotherapy. This function may be particularly efficacious in dealing with minimal residual disease in the 
consolidation cycles of intensive chemotherapy regimens. 
 
We found that ibrutinib inhibits CD117 mediated non-malignant CD34+ cell proliferation, however the degree 
of inhibition was not as pronounced as that observed in the AML blasts. In addition approximately half of the 
CD117 negative AML samples also showed active pBTK. This data suggest the presence of additional receptor 
tyrosine kinases and signalling proteins functioning upstream of BTK in AML. The identification of additional 
receptor tyrosine kinases that signal through BTK in AML may point to other subsets of AML patients who may 
benefit from BTK inhibition. Furthermore it is becoming apparent that ibrutinib appears to inhibit kinases other 
than BTK including mutant EGFR and ITK (40, 41). We and others have previously found that in AML 
ibrutinib treatment mimics data from BTK RNA interference experiments, which argues that at least in AML the 
mechanism of action of ibrutinib is via its inhibitory effect on BTK (17, 42). It is also likely that there are other 
upstream drivers of BTK in AML including FLT3, LYN and SYK (42-44).  Ultimately the clinical significance 
of the BTK signalling pathway and its inhibition by ibrutinib in patients with AML can only fully be defined in 
the context of clinical trials. 
 
To our knowledge we show for the first time that in human AML ibrutinib inhibits the CD117 activation 
pathway and functions to disrupt pro-survival signals from the microenvironment to promote de-adhesion of 
malignant cells from the BMSC and subsequent cell death. This study further validates an emerging focus of 
targeting kinases critical for the survival of malignant cells and gives us a clearer understanding of how 
inhibition of BTK can be harnessed therapeutically in AML. In summary, we provide further biologic rationale 
for clinical trials of ibrutinib to treat patients with AML. 
 
Research in Context 
 BTK is a non-receptor tyrosine kinase overexpressed in 80% of AML (17, 42). 
 Ibrutinib shows efficacy and tolerability (and is licenced for use) in patients with chronic lymphocytic 
leukaemia (CLL) and mantle cell lymphoma and functions through inhibition of BTK downstream of 
the B cell receptor in those diseases. 
 Here we show that in AML, BTK signals downstream of surface CD117 activation and that inhibition 
of BTK by ibrutinib is anti-proliferative and disrupts the interaction between the blasts and the bone 
marrow stromal cells in a mechanism similar to that observed in CLL. 
 In summary we provide biologic data to further support the clinical trial of ibrutinib in patients with 
AML, including those patients whose blasts express CD117.  
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Legends  
Figure 1. SCF/CD117-induced proliferation is inhibited by ibrutinib in primary human AML blasts.  
Primary AML blasts which were (A) CD117pos (n=2) and (B) CD117neg (n=2) and (C) CD34+ HPC (n=4) were 
pre-treated with ibrutinib (500 nM) for 1 hour and then treated with SCF (10 ng/ml) for 72 hours and then 
assessed by BrdU assay. Primary AML patient blasts which were (D) CD117pos (n=11 patient samples) and (E) 
CD117neg (n=8 patient samples) were pre-treated with increasing doses of ibrutinib for 1 hour and then treated 
with SCF (10 ng/ml) for 72 hours and then assessed by CellTiterGlo. (F) Scatterplot of phosphorylated BTK and 
% CD117 expression on AML blasts. (G) Scatterplot of phosphorylated % CD117 expression and ibrutinib IC50 
[µM] in AML blasts.  
 
Figure 2. SCF/CD117-induced BTK phosphorylation in AML. (A) AML#21 (CD117pos) and AML#17 
(CD117neg) were treated with SCF (10 ng/ml) for up to 30mins. Protein extracts were obtained and Western blot 
analysis was conducted for pCD117, CD117, pBTK, BTK. (B) Primary AML blasts which were CD117pos and 
CD117neg were treated with SCF (10 ng/ml) for 5 min and then whole cell extracts were prepared and Western 
blot analysis was conducted for pBTK and total BTK. 
 
Figure 3. SCF/CD117-mediated AML proliferation signals are inhibited by ibrutinib. (A) Primary AML 
blasts which were CD117pos and CD117neg were pre-treated with increasing doses of ibrutinib for 1 hour and 
then treated with SCF (10 ng/ml) for 5 min and then whole cell extracts were prepared and Western blot analysis 
was conducted for pCD117, CD117, pBTK, BTK , pAKT, AKT, pMAPK and MAPK protein levels.  
 
Figure 4. Ibrutinib inhibits SCF/CD117-induced AML adhesion to BMSC. (A) Primary AML blasts which 
were CD117pos (n=4) were either untreated or treated with SCF (10 ng/ml) and then placed onto BMSC for 4 
hours. Cell adhesion was then assessed and expressed as percentage of total cells in the assay. (B) Cell adhesion 
of AML#17 (CD117pos) and AML#23 (CD117neg) AML blasts were pre-treated with ibrutinib (500 nM) for 1 
hour and then treated with SCF (10 ng/ml) and then placed onto BMSC for 4 hours and is expressed as 
percentage of total cells in the assay. (C) CD34+ HPC were pre-treated with ibrutinib (500nM) for 1 hour and 
then treated with SCF (10 ng/ml) and then placed onto BMSC for 4 hours. Cell adhesion was then assessed and 
expressed as percentage of total cells in the assay. (D) Flow cytometry (72 h) showing co-cultured AML blasts 
(CD117pos) and BMSC. (E and F) Primary AML blasts which were CD117pos were treated with various 
concentrations of (E) SCF (0-50 ng/ml) or (F) ibrutinib (0-1000nM) plus SCF (10ng/ml) and then placed onto 
FN coated plates for 4 hours. Cell adhesion was then assessed and expressed as percentage of total cells in the 
assay. The experiments were repeated 4 times using the blasts from AML#26.(G) CD117pos AML blasts were 
pre-treated with ibrutinib (500nM) for 1 hour and then treated with PMA (100nM) and then placed on FN 
coated plates for 1 hour. Cell adhesion was then assessed and expressed as percentage of total cells in the assay. 
Individual results are represented as circles, squares or triangles and median as a horizontal line. The Mann-
Whitney test was used to for comparison between treatment groups (* = p<0.05). 
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Number Age Gender WHO diagnosis Cytogenetics %Blasts 
% 
pBTK/ 
tBTK 
% c-
CD117 
expression 
Ibrutinib 
IC50 
(μM) 
AML#1 78 M 
AML with myelodysplasia related 
changes 
not available 85 54 56 
3 
AML#2 57 M Relapsed AML without maturation not available 95 97 90 5.6 
AML#3 25 M AML with maturation Normal 50* 52 73 - 
AML#4 61 M Relapsed AML without maturation not available Na 38 59 - 
AML#5 26 M 
AML with t(8;21)(q22;q22); 
RUNX1-RUNX1T1 
t(8;21) 60* 80 69 
0.7 
AML#6 28 F 
Acute monoblastic and monocytic 
leukaemia 
Normal 95 54 16 
1.8 
AML#7 40 M AML without maturation Constitutional XXY 95 95 57 2.6 
AML#8 84 M AML, NOS not available 75* 29 0 26 
AML#9 53 M 
AML with t(6;9)(p23;q34);DEK-
NUP214 
t(6;9) 70* 32 69 
9.8 
AML#10 51 F AML with maturation Normal 40* 51 57 5.4 
AML#11 85 F AML NOS not available 60* 65 0 35.6 
AML#12 82 M AMLNOS not available 65* 63 29 2 
AML#13 70 M Therapy-related myeloid neoplasm' Not available n/a 15 8 - 
AML#14 47 M AML without maturation not available 90 77 29 6.6 
AML#15 59 F Acute myelomonocytic leukaemia Normal 20* 13 0 27.8 
AML#16 64 F 
AML with myelodysplasia related 
changes 
Complex 20* 56 70 
3.7 
AML#17 55 F 
Acute monoblastic and monocytic 
leukaemia 
Normal 80 60 0 
58.2 
AML#18 82 M AML with maturation Normal 40* 42 66 7.8 
AML#19 41 F 
AML with t(6;9)(p23;q34);DEK-
NUP214 
t(6;9) >95 76 77 
2 
AML#20 76 M 
AML with myelodysplasia-related 
changes 
Normal 20* 85 67 
8 
AML#21 77 F AML with maturation Normal 65* 81 89 1.6 
AML#22 62 M AML with maturation Complex 55* - 96 - 
AML#23 70 M AML with minimal differentiation Normal >95 81 90 - 
AML#24 65 F AML with maturation Normal 36* - 77 - 
AML#25 40 M AML with minimal differentiation Normal 90 - 65 - 
AML#26 70 M AML without maturation Complex 95 - 93 - 
AML#27 91 F AML NOS Not available 60* 33 16 - 
AML#28 59 F 
AML with t(8;21)(q22;q22); 
RUNX1-RUNX1T1 
t(8;21) 80 39 50 
- 
AML#29 51 M 
Acute monoblastic and monocytic 
leukaemia 
Normal  95 26 0 
- 
 
 
Table 1. AML patient sample information including relative pBTK levels and CD117 expression. This 
table describes the AML patient samples used. Data show WHO diagnosis, cytogenetic results, percent BTK 
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phosphorylation, percent CD117 expression (surface expression on the AML blasts by immunophenotyping) 
and ibrutinib IC50 (μM) where avaiable. “-“ represents data not available.  
 
 
